Fig. 2From: Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative studyOverall survival (a) and progression-free survival (b) in all patients (n = 279). OS: overall survival; PFS: progression–free survivalBack to article page